Current Headlines

  1. Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance 9/25/2026

    Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch clinical development in the United States.

  2. Earendil Labs Announces Research Collaboration With Genentech To Discover And Develop Therapeutic Bispecific Antibodies In Oncology 9/24/2026

    Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology.

  3. Satellos Announces FDA Clearance Of IND Application For Forazapadin In Facioscapulohumeral Muscular Dystrophy (FSHD) And A Partnership With FSHD Canada Foundation Providing Non-Dilutive Financing To Support Clinical Development 9/24/2026

    Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

  4. Commercial Demand For Microgravity Drug Discovery Accelerates As Exobiosphere And Voyager Add Two Missions To The ISS 9/24/2026

    Voyager Technologies and Exobiosphere today announced two additional research campaigns aboard the International Space Station, expanding an agreement that is turning commercial biotech research in microgravity into a recurring, schedulable service rather than a one-off opportunity.

  5. Nexentis: MitoCareX Evaluates Expanded Protein Capabilities To Enhance Flexibility And Support Future Drug Discovery 9/23/2026

    Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.

  6. NIS + Proteos Unite As TrueCourse Biosciences As Demand Surges For Wet-Lab Validation Of AI-Designed Drugs 9/22/2026

    NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have today announced the launch of TrueCourse Biosciences, an integrated CRO that brings together advanced capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex drug discovery programs.

  7. XtalPi AI Enables Seven-Month PCC Nomination For Viva-Thera's MPER-Targeting HIV-1 Program 9/22/2026

    XtalPi (HKEX: 2228) announced that Viva-Thera, a biotechnology company it incubated and backs as a strategic shareholder, has nominated a preclinical candidate (PCC) targeting the membrane-proximal external region (MPER) of HIV-1 gp41.

  8. Adagene Announces NMPA Clearance Of Investigational New Drug Application For ADG138, A Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager 9/22/2026

    Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China’s National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene’s proprietary SAFEbody® precision masking technology.

  9. Circular Genomics And Altoida Announce Collaboration To Advance First-Of-Kind Multimodal Precision Medicine For Alzheimer's Disease 9/22/2026

    Circular Genomics and Altoida today announced a collaboration combining Circular Genomics' blood-based circular RNA (circRNA) biomarker platform with Altoida's AI-powered Digital NeuroMarker™ platform.

  10. X-Chem Announces Phase 3 Milestone In Collaboration With Relay Therapeutics 9/22/2026

    X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen.